Table S2: Characteristics of participants not using the pillbox in the intervention interval

	Control (*n* =14)	**Intervention (*n* = 17)**
Demographics		
Median age in y *(IQR)*	17.4 (12.9 – 18.6)	15.5 (12.5 – 17.1)
Male (%)	9 (64.3)	7 (41.2)
Race		
White (%)	12 (85.7)	13 (76.5)
Black (%)	1 (7.1)	2 (11.8)
Asian (%)	0 (0.0)	0 (0.0)
Other (%)	1 (7.1)	2 (11.8)
Hispanic (%)	1 (7.1)	1 (5.9)
U.S. Study site (%)	10 (71.4)	14 (82.4)
Healthcare Insurer		
U.S. Public	3 (21.4)	7 (41.2)
Private	7 (50.0)	7 (41.2)
Canadian provincial	4 (28.6)	3 (17.7)
Medication Insurer		
U.S. Public	3 (21.4)	6 (35.3)
Private	10 (71.4)	11 (64.7)
Canadian provincial	1 (7.1)	0 (0.0)
Primary caregiver		
Mother	11 (78.6)	10 (58.8)
Father	2 (14.3)	4 (23.5)
Grandparent	0 (0.0)	1 (5.9)
Self	1 (7.1)	2 (11.8)
Education of primary caregiver		
Less than high school	0 (0.0)	1 (5.9)
High school	4 (28.6)	4 (23.5)
Some college	5 (35.7)	6 (35.3)
Completed Business/Trade/Technical School	2 (14.3)	2 (11.8)
College graduate	3 (21.4)	3 (17.7)
Completed Graduate School	0 (0.0)	1 (5.9)
Adults in household (number, not including pt)		
0	3 (21.4)	1 (5.9)
1	2 (14.3)	3 (17.7)
2	4 (28.6)	9 (52.9)
≥3	5 (35.7)	4 (23.5)
Household income		
Less Than $25,000	1 (7.1)	3 (17.7)
$25,000 - $50,000	3 (21.4)	4 (23.5)
$51,000 - $75,000	5 (35.7)	6 (35.3)
$76,000 - $100,000	2 (14.3)	0 (0.0)
Greater Than $100,000	0 (0.0)	2 (11.8)
Prefer Not to Answer	0 (0.0)	0 (0.0)
Unknown	3 (21.4)	2 (11.8)
Disease characteristics		

Median years post-transplant (IQR)	3.0 (0.8 – 7.2)	3.7 (0.7 – 7.9)
Total number of transplants		
1	13 (92.9)	17 (100.0)
2	1 (7.1)	0 (0.0)
Donor source		
Living	5 (35.7)	12 (70.6)
Deceased	9 (64.3)	5 (29.4)
Median total lifetime duration of dialysis in months (IQR)	3.0 (0.0 – 24.0)	10.0 (0.3 – 15.0)
Median age at transplant in years (IQR)	11.7 (5.1 – 16.9)	9.9 (7.6 – 14.8)
Primary disease		
CAKUT (%)	8 (57.1)	5 (29.4)
Glomerulonephritis (%)	0 (0.0)	0 (0.0)
FSGS (%)	0 (0.0)	6 (35.3)
Other (%)	6 (42.9)	6 (35.3)
Number of past acute rejections		
0 (%)	14 (100.0)	17 (100.0)
1 (%)	0 (0.0)	0 (0.0)
Comorbidities		
None	5 (35.7)	7 (41.2)
≥1*	9 (64.3)	10 (58.8)
Median eGFR at baseline (ml/min/1.73m^2; IQR)	66.3 (53.3 – 86.6)	53.7 (42.5 – 58.1)
Treatment characteristics:		
Number of immunosuppressive medications		
1	0 (0.0)	0 (0.0)
2	10 (71.4)	9 (52.9)
3	4 (28.6)	8 (47.1)
Number of doses of immunosuppressives per day		
1	0 (0.0)	2 (11.8)
2	14 (100.0)	15 (88.2)
Median total number of medications (IQR)	6.0 (5.0 – 8.0)	7.0 (5.0 – 7.0)
Total number of doses per day		
1	0 (0.0)	0 (0.0)
2	14 (100.0)	16 (94.1)
3	0 (0.0)	0 (0.0)
4	0 (0.0)	1 (5.9)
Pre-intervention adherence and barriers		
Run-in electronic adherence data		
Median taking adherence (% all prescribed doses taken) (IQR) †	n/a	n/a
Median timing adherence (% all prescribed doses taken on time) (IQR) †	n/a	n/a
Standard deviation of tacrolimus levels in the 6 months before intervention		
Once per day formulation (mean ± SD)*	n/a	n/a
Twice per day formulation (mean ± SD)**	1.5 ± 0.8	2.8 ± 2.1
Self-reported adherence (MAM; enrollment)		
Taking adherence (mean ± SD)	98.0 ± 4.4	97.9 ± 4.9
Timing adherence (mean ± SD)	91.3 ± 11.9	91.6 ± 11.9

Adherence barriers (AMBS) scores Total score (mean ± SD)	36.0 ± 9.2	40.8 ± 7.2
Adherence barriers (PMBS) scores Total score (mean ± SD)	36.5 ± 7.9	38.0 ± 6.9
Time in study and coach contact time		
Run-in interval		
Median patient-months (IQR)	3.1 (3.0 – 3.2)	3.3 (2.8 – 5.4)
Median time spent with coach (minutes; IQR) Enrollment visit	45.0 (40.0 – 60.0)	40.0 (35.0 – 57.0)
Intervention interval		
Median patient-months (IQR)	12.2 (10.7 – 12.9)	10.1 (4.6 – 12.7)
Median time spent with coach (minutes; IQR) 1st Intervention visit (3 mo.) 6-month visit 9-month visit 12-month visit 15-month visit	 25.0 (20.0 – 35.0) 24.0 (20.0 – 29.5) 20.0 (16.0 – 33.0) 22.5 (20.0 – 28.5) 29.0 (25.0 – 35.0)	 67.5 (55.0 – 80.0) 34.5 (23.5 – 45.0) 30.0 (26.0 – 32.0) 32.0 (30.0 – 33.0) 33.5 (20.0 – 37.5)

*There was only 1 patient (intervention) taking once per day tacrolimus.
**7 control and 3 intervention patients with ≥3 trough levels available to calculate SD
†There were insufficient pillbox data available on these participants to calculate taking and timing adherence during the run-in.